Investments Panel at Ocular Drug Discovery Meeting- March, 2014 in San Diego, CA

raniah@gtcbio.com's picture
Printer-friendly versionPrinter-friendly versionPDF versionPDF version

Investments and Collaborations Panel at the 6th Ocular Diseases & Drug Discovery Conference on March 20-21, 2014 in San Diego, CA


San Diego, CA, United States., December 19, 2013 - (PressReleasePoint) - GTC’s 6th Annual Ocular Diseases & Drug Discovery Conference held on March 20-21, 2014 in San Diego, CA will feature a panel discussion on Business Development, Investments and Potential for Collaborations.
 
The panelists include Ken Mandel, President & CEO at LayerBio; Ali Behbahani, Principal at New Enterprise Associates; Emmett Cunningham, Partner at Clarus Ventures and Patrick Johnson, Director of Business Development at Allergan.

The panel will discuss the current state of ophthalmology development and how collaborative relationships are designed. Further discussion will include topics on venture financing, environment for startups and later stage ophthalmology companies, corporate venture appetite in the ophthalmology space, areas of investment interest, IPO markets and drugs vs device investments.
 
The Ocular Diseases & Drug Discovery Conference continues to promote the discovery of ocular disease by offering presentations on novel and innovative therapeutics in ocular drug development and discovery. The conference brings together leading scientists, researchers and experts to discuss and collaborate on the latest research, safety assessment, and regulatory issues. Highlights include drugs in development for combating and curing age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, DME, uveitis and other ocular diseases.
 
For more information, please visit www.gtcbio.com/ocular  


Press Contact:
Kristen Starkey
Global Technology Community | 635 W. Foothill Blvd | Monrovia, CA 91016
6262566405
www.gtcbio.com
**********@g**b**.com
Email partially hidden to block spam. Please use the contact form here.
Contact Kristen Starkey
Email the contact person for this press release. Do not send spam or irrelevant message.
1 + 0 =


Copy this html code to your website/blog to embed this press release.

Comments

Post new comment

10 + 3 =